Causeway Therapeutics
@CausewayThera
Followers
161
Following
4
Media
6
Statuses
27
We are The Tendon Health Company, a clinical-stage biotech developing novel medicines for tendon disease.
Joined August 2017
#ICYMI, we debuted data from our Phase 2 trial of TenoMiR® in lateral epicondylitis, showing for the 1st time that a miR29a therapy relieves symptoms & improves tendon healing when correctly delivered into the tendinopathic lesion. Read our release: https://t.co/fHL6CYAFip
0
1
1
Excited to share @endpts' coverage of our Phase 2 clinical data showing that when properly injected with a single dose of TenoMiR®, patients with lateral epicondylitis showed statistically significant improvements in pain, function & tendon structure:
endpoints.news
Causeway Therapeutics' microRNA drug for tennis elbow missed primary endpoint in Phase 2, but showed promise in properly injected patients. Plans Phase 3 amid $150M+ fundraising.
0
1
1
Did you know that each year more than 11 million people in the US experience symptoms of tendinopathy? We are developing treatments to address the molecular cause of tendon disease, not just alleviate symptoms. Visit https://t.co/kh539czZw5 to learn more.
0
1
1
Did you see Causeway’s new website? Check it out and sign up to learn more about forthcoming data announcements and clinical trials for our phase 2 clinical candidate, TenoMiR®, a treatment for patients with lateral epicondylitis (tennis elbow): https://t.co/ALcVthxECe
0
1
1
Meet Derek Gilchrist, PhD, Causeway’s Co-founder and Chief Science Officer. He leads the scientific development of TenoMiR®, a therapeutic now in a phase 2 clinical trial for patients with lateral epicondyle tendinopathy (tennis elbow). Learn more here: https://t.co/72l6vc73yl
0
0
3
We are delighted to launch the new Causeway website! Sign up to learn more about forthcoming announcements and clinical trials for TenoMiR®, a treatment for patients with lateral epicondylitis (tennis elbow). Check it out here: https://t.co/ALcVthxECe!
causewaytx.com
The Tendon Health Company: Causeway Therapeutics is developing first-in-class microRNA therapies with the potential to improve quality of life for those suffering from tendinopathy.
0
1
4
It is also important to acknowledge the support we have received from @scotent, @UofGlasgow, @innovateuk, which was essential for the development of TenoMiR.
0
1
4
A multi-site Phase 2 trial will start recruiting over the summer that we are confident will build on the remarkable results from TenoMiR’s Phase 1b study. Exciting times ahead! #Tenniselbow, #tendinopathy, #lateralepicondylitis.
1
1
3
@causewaythera would like to thank our investors for our recent £8.75M investment, which will allow Causeway to continue developing TenoMiR to treat lateral epicondylitis (tennis elbow).
2
1
6
Causeway Therapeutics secures £8.75 million for Phase 2 trial of #tendinopathy therapy @UofGlasgow spin-out will use funds to advance development of #microRNA therapeutics. @CausewayThera #tenniselbow
https://t.co/LhCi0tlo01
longevity.technology
Glasgow University spin-out will use funds to advance development of microRNA therapeutics.
0
5
11
The lab work hasn't stopped just because we've moved into the clinic, our R&D team is hard at work developing new therapies for other musculoskeletal diseases. Exciting times ahead!! #tendinopathy
0
1
3
However, special acknowledgment and thanks go to the @UofGlasgow, @scotent and @innovateuk whose funding allowed us to make it this far. We would also like to thank @IainBMcInnes for his support and encouragement throughout, without which Causeway would not exist.
2
1
4
It's been a long, challenging journey since that initial spark of inspiration in the lab that @derekgilchrist1 and @TendonGlasgow to create TenoMiR. So many people and institutions deserve credit for this milestone that it would be impossible to list them all here.
1
0
1
Causeway Therapeutics is delighted to announce that we are now officially a clinical-stage company. Our first cohort of patients with lateral epicondylitis (tennis elbow) has begun receiving TenoMiR.
1
4
13
Causeway Therapeutics is grateful to @innovateuk for the award of £1.3m towards the development of TenoMiR our promising tendinopathy therapy. The funding will accelerate TenoMiR's development leading to First in Patient clinical trials in 2019. @iiiglasgow @UofGMVLS
Thanks to @innovateuk for awarding £1.3m biomedical catalyst grant to @CausewayThera and @TendonGlasgow to continue our #microRNA #tendinopathy work with planned Phase I human trials in 2019! @UofGMVLS @iiiglasgow @UofGInnovation #maketendonpatientsbetter
0
5
18
@CausewayThera is developing therapies based on this research for the treatment of tendinopathy in humans and horses.
It's great to see @CausewayThera, @UofGlasgow and @iiiglasgow research getting front cover of @MolTherapy.
0
0
1
It's great to see @CausewayThera, @UofGlasgow and @iiiglasgow research getting front cover of @MolTherapy.
Front cover of this months @MolTherapy
https://t.co/3PX8R7ablw … showing our work on microRNA29a in @tendon injury @iiiglasgow @moeed_akbar
1
3
5
BBC News - In pictures: Photographer 'in awe' of older athletes https://t.co/zacyyu5bYF
@CausewayThera is also in awe!
bbc.co.uk
The athletes in their 60s, 70s, 80s and 90s competing for glory across the world.
0
0
1
Causeway Therapeutics announces seed investment - https://t.co/8DStBO3CJM
https://t.co/Jir1chRA7x
#Medicine #LifeSciences #myscience
0
1
2
University spin-out raises £1m to develop new tendon injury treatment
0
1
2